Moving Prostate Cancer Polygenic Risk Scores from Research Towards Clinical Practice

Eur Urol Focus. 2022 Jul;8(4):913-915. doi: 10.1016/j.euf.2022.08.011. Epub 2022 Aug 31.

Abstract

Recent advances in our understanding of genetic factors that contribute to prostate cancer (PCa) susceptibility have the potential to improve disease screening, diagnosis, and treatment. Genetic risk scores in particular can more accurately inform patients of their risk of being diagnosed with PCa, which may help in decisions on whether to undergo prostate-specific antigen screening or prostate biopsy. Genetic information may also be useful in helping patients understand the etiology of their PCa and whether their family members should undergo more intensive screening. PATIENT SUMMARY: This mini review discusses recent advances in our understanding of how genetic factors influence a man's risk of developing prostate cancer. This information has the potential to improve screening, diagnosis, and patient counseling following a diagnosis of prostate cancer.

Publication types

  • Review

MeSH terms

  • Humans
  • Male
  • Prostate / pathology
  • Prostate-Specific Antigen*
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / pathology
  • Risk Assessment
  • Risk Factors

Substances

  • Prostate-Specific Antigen